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Abstract
Background: Rituximab has been widely used off-label as a second line treatment for children with immune
thrombocytopenia (ITP). However, its role in the management of pediatric ITP requires clarification. To understand and
interpret the available evidence, we conducted a systematic review to assess the efficacy and safety of rituximab for children
with ITP.
Methodology/Principal Findings: We searched MEDLINE, EMBASE, Cochrane Library, CBM, CNKI, abstract databases of
American Society of Hematology, American Society of Clinical Oncology and Pediatric Academic Society. Clinical studies
published in full text or abstract only in any language that met predefined inclusion criteria were eligible. Efficacy analysis
was restricted to studies enrolling 5 or more patients. Safety was evaluated from all studies that reported data of toxicity. 14
studies (323 patients) were included for efficacy assessment in children with primary ITP. The pooled complete response
(platelet count $100610
9/L) and response (platelet count $30610
9/L) rate after rituximab treatment were 39% (95% CI,
30% to 49%) and 68% (95%CI, 58% to 77%), respectively, with median response duration of 12.8 month. 4 studies (29
patients) were included for efficacy assessment in children with secondary ITP. 11 (64.7%) of 17 patients associated with
Evans syndrome achieved response. All 6 patients with systemic lupus erythematosus associated ITP and all 6 patients with
autoimmune lymphoproliferative syndrome associated ITP achieved response. 91 patients experienced 108 adverse events
associated with rituximab, among that, 91 (84.3%) were mild to moderate, and no death was reported.
Conclusions/Significance: Randomized controlled studies on effect of rituximab for children with ITP are urgently needed,
although a series of uncontrolled studies found that rituximab resulted in a good platelet count response both in children
with primary and children secondary ITP. Most adverse events associated with rituximab were mild to moderate, and no
death was reported.
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Introduction
Immune thrombocytopenia (ITP) is an immune-mediated
disease characterized by transient or persistent decrease of the
platelet count and increased risk of bleeding [1]. The incidence of
ITP is 1.9,6.4 per 10
5 children/year [2] and 23.1%,47.3% of
children with ITP suffer a disease course more than 6 months [3].
The goal of ITP treatment is to achieve a platelet count that is
associated with adequate hemostasis, rather than a ‘‘normal’’
platelet count. The recommended first-line drug treatment for
children with ITP includes corticosteroids, intravenous immuno-
globulin (IVIg) and Anti-D immunoglobulin [4], but for pediatric
patients refractory to first line treatment, appropriate second line
treatments are needed.
Rituximab is a chimeric, monoclonal anti-CD20 antibody that
targets B lymphocytes and causes Fc-mediated cell lysis [5,6]. It
was initially approved for the treatment of lymphoma, as it can
substantially decrease the normal and malignant B-cells [7]. It has
also been approved for the treatment of rheumatoid arthritis in
Europe, as it can destroy B lymphocytes in the joints to help
reducing inflammation [8]. In recent years, it has been widely used
off-label as the second line treatment in both adults and children
with ITP refractory to first line treatment. A systematic review
based on studies on adult patients with ITP found that rituximab
resulted in overall response (platelet count .50610
9/L) and
complete response (platelet count .150610
9/L) in 62.5% and
43.6% of patients, respectively [9]. Several studies on children
suggested that rituximab showed a similar effect as adult ITP, but
the reported response rate varied among those studies [10]. In
addition, those results may be potentially biased and imprecise, as
most studies are case series, and only involved a relatively small
number of patients. The role of rituximab in the management of
pediatric ITP still requires clarification. To understand and
interpret the available evidence, we conducted a systematic review
to evaluate the efficacy and safety of rituximab for children with
ITP.
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Searching
We searched PUBMED, EMBASE, Cochrane Central Register
of Controlled Trials (CENTRAL) published in Cochran Library
(2012, Issue 1) using the search strategy detailed in table S1; we
searched Chinese Biomedical Literature Database (CBM) and
Chinese National Knowledge Infrastructure (CNKI) for literatures
published in Chinese. We also searched the electronic databases of
American Society of Hematology, American Society of Clinical
Oncology and Abstract Database of Pediatric Academic Society
including its Late-Breaker Abstract Presentations,with the search
term ritux*, child* and pediatr*. The references of all retrieved
articles were scanned for additional relevant citations. We
searched all databases from their earliest records to January 2012.
Eligibility Criteria
Clinical studies published in full text or abstract only were both
included, and there was no restriction on study design or
publication language. We included children aged less than 18
years with primary or secondary ITP, having platelet counts less
than 30610
9 cell/L. Studies that included both children and
adults were excluded if data of children could not be extracted
separately. Patients were treated with rituximab irrespective of
dosage and schedule. Outcome criteria based on guidance recently
provided by international working group (IWG) consensus panel of
both adult and pediatric experts [1]. Response (R) was defined as
any platelet count $30610
9/L and at least doubling of the
baseline count. Complete response (CR) was defined as any
platelet count $100610
9/L. Time to response was from starting
treatment to achievement of response. Duration of response was
measured from the achievement to loss of response. All reported
adverse events were included for safety assessment. Studies that
enrolled fewer than 5 patients but failed to contribute to safety
analysis were excluded.
Study Selection and Data Abstraction
Two authors (Yi Liang and Die Hu) independently screened
titles and abstracts of all studies identified by the search strategy
and assessed the studies for inclusion using predetermined
inclusion criteria. The full texts of all potentially relevant articles
were retrieved for detailed review. We resolved disagreements by
discussion until consensus is achieved.
Two authors (Yi Liang and Die Hu) used a pre-designed data
collection form to independently extract data from each included
study. The following data were extracted: (1) characteristics of
patients, including number of patients that meet the inclusion
criteria, country, age, primary/secondary ITP, duration of ITP,
splenectomized or not, and platelet count before rituximab
treatment; (2) study design and use of controls; (3) dose and
schedule of rituximab; (4) number of patients with platelet count
response, complete response, and their definitions; (5) time to
platelet count responses; (6) follow-up and duration of platelet
count responses; (7)toxicities associated with rituximab; (8) source
of funding.
Quality Assessment
Quality assessment was based on the checklist developed for
assessment of case series by UK national institute for clinical
excellence (NICE) [11]. We answered 8 questions included in the
checklist with yes, no, or unclear. Quality assessment was only
conducted in studies enrolling 5 or more patients, as those studies
contributed to efficacy analysis.
Statistical Synthesis
Platelet count responses were analyzed only from those studies
enrolling 5 or more patients, as smaller studies may be subject to
extreme risk of reporting and selection bias. Adverse effects were
considered from all studies, including those enrolling fewer than 5
patients each. We achieved exact binomial 95% confidence
interval (CI) of response rate reported in each study. We estimated
the between-study variance and determined pooled estimates of
response rate using the software STATA 11.1 with a random-
effect model [12]. Time to response and response duration were
described with medians, minimum and maximum values, and for
studies that reported individual level data, we combined and
summarized these data with medians and inter quartile ranges
(IQR). We assessed publication bias both with Egger and Begg test
in STATA 11.1, and P, =0.05 suggested a significant publication
bias [13,14].
We calculated a kappa statistic for measuring agreement
between two authors making decisions on study selection. Values
of kappa between 0.40 and 0.59 were considered to reflect fair
agreement, between 0.60 and 0.74 to reflect good agreement and
0.75 or more to reflect excellent agreement [15]. The design and
report of this review has been checked with PRISMA checklist (see
table S2).
Results
Study Selection
1280 citations were identified from the literature search, and 30
studies [16–45] (370 patients) were included in this systematic
review. 18 studies [16–33] (352 patients) enrolled 5 or more
patients each, among which 5 studies [29–33] (59 patients) were
published only in abstract; 12 studies [34–45] (18 patients) enrolled
less than 5 patients each, among which 2 studies [34,38] (6
patients) were published in abstract. Figure 1 shows the literature
selection process. Agreement between 2 reviewers for study
selection was excellent (K=0.75).
Study Design and Source of Funding
17 case series [16–27,29–33], 12 case reports [34–45] and 1
longitudinal observational cohort study were included in this
systematic review. The cohort study included a control group
involving patients without rituximab administration, but only
reported concerned outcomes in the rituximab group, failing to
make a comparison on effects between two groups [28]. 9 studies
[17–19,24,28,31,37,39,40] were supported by non-profit organi-
zations; 4 study did not receive any funding source [21,22,33,42];
Source of funding was not reported in the other 17 studies.
Quality Assessment
18 studies [16–33] enrolling 5 or more patients were involved in
the quality assessment (table 1). 10/18 studies were multicenter
studies; All studies described their hypothesis/objective and main
findings clearly; 14/18 studies clearly defined outcomes; 9/18
studies clearly described patient inclusion criteria; 9/18 studies
collected patients data prospectively, 1 cohort study collected data
both prospectively and retrospectively; Only 1 study stated
consecutive enrollment of patients, none of other studies provided
this information, although it is necessary, as consecutive enroll-
ment may reduce risk of selection bias; Platelet count response was
stratified in 5 studies by clinical characters of patients to find
predictors of response to rituximab.
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352 patients were included in 18 studies enrolling 5 or more
patients. Characteristics of these patients were described in table 2.
171 (48.6%) patients in 6 studies [17,18,20,22,24,28] were from
USA/Canada, and 181 (51.4%) patients were from other
countries, including Germany [16], Italy [23], France [19] Czech
Republic [31],Portugal [32], China [26,27,33], Turkey [21,25],
South Korea [30] and India [29]. 304 patients were diagnosed as
primary ITP, and 48 cases were diagnosed as secondary ITP
associated with other diseases, including Evans syndrome, systemic
lupus erythematosus, and autoimmune lymphoproliferative syn-
drome. The patients were from 0.5 to 19 years old and had a
duration of ITP from 0.2 to 175 months, with platelet count from
1t o7 5 610
9/L before rituximab treatment, according to studies
that provided data on these items. Treatments before rituximab
varied between and within studies. IVIG, steroid, and anti-D were
most commonly used, other previous treatment included splenec-
tomy, cyclophosphamide, ciclosporin, azathioprine, vincristine,
danazol, hydroxychloroquine and mycophenolate mofetil.
Rituximab Dose and Schedule
Doses of rituximab were reported in 16 studies (265 patients)
(see table 2). 224 (84.5%) patients received intravenously rituximab
as a dose of 375 mg/m
2/week for 1,6 doses. Among that, 175
(66.0%) patients received 4 doses; 22 (8.3%) patients received 1
dose; 10 (3.8%) patients received 6 doses; 7 (2.6%) patients
received 2 doses; 6 (2.3%) patients received 3 doses; 4 (1.5%)
patients received 5 doses. 4 (1.5%) patients received a second
course of 3,4 doses of 375 mg/m
2/week rituximab [22,24], and
9 (3.4%) patients received dose escalation to 750 mg/m
2/dose as
no response after 3 doses [20]. 18 (6.9%) patients received
100 mg/dose/week for 4 doses [26,27] considering the high cost
of rituximab. 2 patients received 500 mg/m
2/dose every 2 weeks
for 2 doses [22]. 21 patients received 1 dose of 375 mg/m
2 or 4
Figure 1. Flow diagram of study selection process for this systematic review. This is a modified four-phase PRISMA 2009 flow diagram that
maps out the number of records identified, included and excluded, and the reasons for exclusions.
doi:10.1371/journal.pone.0036698.g001
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as published in abstract only [33].
Platelet Count Response
Primary ITP. Response and complete response were defined
with varied platelet count thresholds in the primary studies. We
calculated the pooled response rate according to criteria defined in
this systematic review. Response (platelet count $30610
9/L) after
rituximab treatment was reported in 14 studies [16–
18,20,21,23,25–29,31–33] involving 312 patients, and was
achieved in 201 patients (64.4%). 19 (6%) patients, although
diagnosed as secondary ITP, were still included in the analysis as
their data can not be separated. The response rate reported in the
primary studies ranged from 33% [18] to 100% [27], and the
pooled rate was 68% (95% CI, 58% to 77%). The heterogeneity
between studies was statistically significant (P,0.001) (Figure 2).
Complete response was reported in 14 studies [16–
18,20,21,23,25–27,29–33] involving 243 patients, and was
achieved in 99 patients (40.7%). The reported complete response
rate ranged from 14% [33] to 67% [26], and the pooled rate was
39% (95%CI, 30% to 49%). The heterogeneity was statistically
significant (P=0.005) (Figure 3).
Secondary ITP. 4 studies [18,19,22,24] reported data of 29
children with secondary ITP separately. 17 children with Evans
syndrome associated ITP wereincluded in2studies[18,19], among
that 11 (64.7%) children achieved response and 9 (52.9%) achieved
complete response. 6 children with systemic lupus erythematosus
and 6 patients with autoimmune lymphoproliferative syndrome
associated ITP all (100%) achieved complete response. [22,24].
Time to Response and Response Duration
Primary ITP. Time to response was reported in 8 studies
[17,18,21,23,25,26,27,30] (97 patients with response), ranging
from 0.3 to 17.0 weeks [23]. Individual level data was reported in
2 studies [21,23] (40 patients with response), the combined median
time to response was 3.0 (IQR, 1.0 to 3.6) weeks. Response
duration was reported in 8 studies [17,18,21,23,25,26,27,32] (97
patients with response), ranging from 0.9 to 74.8 months [23], but
among that, 63 patients (64.9%) were still having ongoing response
when the follow-up ended. Individual level data was reported in 4
studies [17,21,23,32] (62 patients with response), the median
response duration was 12.8 (IQR, 4.5 to 25.1) months, among
that, 35 patients (56.5%) were having ongoing response when the
follow-up ended.
Secondary ITP. 7 patients with Evans syndrome associated
ITP achieved response with time to response from 0.8 to 8 weeks,
and none relapsed after 8 to 20 months follow-up [19]. 6 patients
with systemic lupus erythematosus associated ITP achieved
response with time to response from 1 to 12 weeks, among that,
2 patients relapsed at 12 and 17 months, but both achieved
complete response again after a second course of rituximab, other
patients had ongoing response from 6 to 22 months [22]. 2 of 6
patients with autoimmune lymphoproliferative syndrome associ-
ated ITP relapsed at 15 and 18 months, the other 4 patients had
Figure 2. Response rate to rituximab in children with ITP. This forest plot is created by the software of STATA 11.1. Solid boxes indicate the
response rate in each study. Horizontal lines indicated 95% CIs. The diamond indicates the pooled response rate (68%). Test of heterogeneity:
I
2=67.5%, P,0.001.
doi:10.1371/journal.pone.0036698.g002
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response was not reported [24].
Predictors of Response to Rituximab
4 studies [18,23,28,29] (175 patients) analyzed clinical charac-
teristics associated with platelet count response to rituximab,
however, their results varied. Bennett 2005 [18] (36 patients)
found that attainment of response was weakly associated with
diagnosis of Evans syndrome (P=0.06), female sex (P=0.14) and
black race (P=0.09), but the reported P value did not show
significance association (P.0.05). Parodi 2009 [23] (49 patients)
founded that median duration of ITP was significantly shorter in
responders than in non-responders (P=0.01). Grace 2012 [28],
which was the largest (80 patients), showed that secondary ITP
and response to steroid were strong predictors of response to
rituximab, and was both suggested by result of univariate and
multivariable analysis. Sharma 2005 [29] reported that patients
showing a higher degree of response continued to be in remission
for a longer period compared to ones with lesser degree of
response.
Toxicities
23 studies reported 108 adverse events in 91 patients. In 11
studies (190 patients) enrolling more than 5 patients, 78 (41.1%)
patients experienced adverse events. Adverse events were classified
from Grade 1 to 5 according to Common Terminology Criteria
for Adverse Events (CTCAE) [46], and were described in table 3.
In all reported 108 adverse events, 91 (84.3%) were mild to
moderate, and the most frequently described adverse events are
mild allergic reactions, including pruritus, urticaria, chills and
fever. 7 patients developed serum sickness after 1 or 2 doses of
rituximab, presented with fever, rash, arthralgia and fatigue, and
in which, 3 cases were assigned to Grade 3–4, as 1 patient has an
acute reaction followed by persistent arthralgia and 2 patients
discontinued rituximab for serum sickness [17,18]. 2 patients
experienced immediate hypersensitivity reaction during rituximab
infusion, which caused termination of the treatment [20,45]. 4
patients developed infections that may be associated with
rituximab, including 2 patients with varicella [18,34], 1 patient
with pneumonia [19], and 1 patient with life-threatening
enteroviral meningoencephalitis presented with a progressive
alteration in cognitive functions associated with aphasia and
sensorimotor deafness [36]. 1 patient developed common variable
immunodeficiency which caused prolonged hypogammaglobulin-
emia and increased susceptibility to infections [41]. 1 patient
developed headache with white matter changes on brain MRI, as
only described in abstract, no further information was reported
[38]. No death associated with rituximab was reported.
Publication Bias
The Egger and Begg test were conducted to investigate
publication bias in 14 studies reporting response in patients with
Figure 3. Complete response rate to rituximab in children with ITP. The diamond indicates the pooled complete response rate (39%). Test of
heterogeneity: I
2=56.7%, P=0.005.
doi:10.1371/journal.pone.0036698.g003
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bias (P=0.987). Begg’s funnel plot with pseudo 95% (figure 4) was
graphed in the logic that studies with smaller sample size have
larger random error, thus are more dispersed, and the plot of effect
estimates against standard errors would be skewed and asymmet-
rical in the presence of publication bias. In this review, the funnel
plot suggests no significant asymmetry, indicating no evidence of
substantial publication bias (P=0.583).
Discussion
This is the first systematic review that summarizes the efficacy
and safety of rituximab in children with ITP, and this review is
very important at this time as rituximab has been widely used off-
label for children with ITP. The treatment of rituximab achieved
response in 68% and complete response in 39% of patients with
primary ITP. According to studies reporting individual data, the
median time to response was 3.0 weeks and the median response
duration was 12.8 months. Studies with a small number of patients
with secondary ITP reported that response rate to rituximab was
from 64.7%,100%. Most adverse events were mild to moderate
and no death was reported.
The response and complete response rate in children with
primary ITP obtained in this review was 68% and 39%,
respectively. It was similar to that reported in the previous
systematic review on adults, which reported that overall response
(platelet count .50610
9/L) and complete response (platelet count
.150610
9/L) rate was 63% and 46% respectively [9]. Although
Table 3. Adverse events observed after rituximab infusion in children with ITP.
Study
ITP Patients,
n
Patients
experienced
adverse events, n Adverse events (n)
Grade 1–2 Grade 3–4 Grade 5
Lorenzana, (2002)* [34] 3 1 NR Viral infection (varicella) (1); Central
venous line infection (1)
None
Bengtson, (2003) [35] 1 1 Rash(1); Elevated serum IgE level (1) None None
Quartier (2003) [36] 1 1 NR Enteroviral meningoencephalitis (1) None
Pusiol (2004) [37] 2 1 Fever and chill (1) None None
Sharma (2005)* [29] 10 3 Urticaria (1); Fever(2) None None
Wang, (2005) [17] 24 9 Pruritus (1); Throat tightness (1);
Urticaria(3); Headache (3); Chest pain (1);
Serum sickness (2); Low ANC (3)
Serum sickness (1) None
Bennett, (2006) [18] 36 23 Chills, fever, and respiratory
symptoms (17)
Serum sickness (2); Viral infection
(varicella) (1); Hypotension (1)
None
Yadav, (2006)* [38] 3 1 Drowsiness (1) Hypotension(1); White matter
changes on MRI (1)
None
Bader-Meunier
(2007) [19]
11 7 Vomiting(1); Facial edema(1);
Urticarial rash(1)
Transient neutropenia (3); Pneumonia(1) None
Bisogno (2007) [39] 1 1 Persistent B-cell depletion and
hypogammaglobulinemia (1)
NR None
Kim (2007) [40] 1 1 Fatigue and malaise (1) NR None
Gentner,(2008) [41] 1 1 NR Common variable immunodeficiency (1) None
Parodi, (2009) [23] 49 9 Urticaria (4); Mild headache (3);
Chills (3); Fever (2)
None None
Rao,(2008) [20] 19 15 Cough (4); Rash (3); Muscle cramps (3);
Headache (2); Shortness of breath (1);
Hypertension (1); Chills (1); Fever (1);
Angioedema (1)
Immediate hypersensitivity reaction(1) None
Adeli,(2009) [42] 2 2 Persistent hypogammaglobulinemia (2) NR None
Cooper (2009) [43] 1 1 Persistent B-celldepletion and
hypogammaglobulinemia (1)
NR None
Dogan, (2009) [21] 10 3 Itching and scraps(3) None None
Goto (2009) [44] 1 1 Serum sickness (1) NR None
Rao (2009) [24] 6 3 Persistent hypogammaglobulinemia (3) NR None
Sampaio (2010)* [32] 7 3 Pruritus (1); Urticaria (1); Vomiting (1) None None
Romanos-Sirakis (2011)
[45]
1 1 Serum sickness (1) Immediate hypersensitivity reaction(1) None
Xu (2011) [26] 9 2 Fever and chill (2); Urticaria (2) None None
Yang (2011) [27] 9 1 Pruritus (1) None None
NR: not reported * Abstract.
Grade 1-Grade 2: Mild to moderate; Grade 3: Severe but not immediately life-threatening; Grade 4: Life-threatening; Grade 5: Death.
ANC: absolute neutrophil count; MRI: magnetic resonance imaging.
doi:10.1371/journal.pone.0036698.t003
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rituximab results in a similar response in adults and children with
primary ITP.
The frequently administrated dose of rituximab is 375 mg/m
2
per week for 4 weeks for both children and adult with ITP [9],
although this dose was developed and approved for the treatment
of lymphoma [47]. 1 study investigated the efficacy of a single dose
of rituximab (375 mg/m
2) in children, and reported a similar
response and complete response rate as 4 doses [16]. 2 studies
investigated a low dose rituximab of 100 mg/dose/week for 4
weeks in 18 children with primary ITP, which suggested that the
lower dose of rituximab still reached a good response [26,27].
Treatment of rituximab is still costly in the present time, and thus
sometimes 4 doses of 375 mg/m
2 are not affordable, especially for
patients with poor accessibility to health resources. In addition,
high dose and multiple dosing may increase risk of adverse events.
Low dose of rituximab may be promising for patients with ITP,
and more studies are needed to investigate that.
Most of adverse events associated with rituximab in children
with ITP were mild to moderate infusional reactions. More severe
adverse effects included serum sickness, common variable immu-
nodeficiency, severe virus infection including enteroviral menin-
goencephalitis, and white matter changes. 2 children developed
viral infection after rituximab treatment, but they were both
previously treated with other immunosuppressive agents like
steroids, vincristine, and cyclosporine A, it is difficult to establish
a direct association with rituximab [18,34]. In addition, a
systematic review in cancer patients did not find any increase of
infection caused by monoclonal antibodies [48]. The case of
common variable immunodeficiency in patients with ITP after
rituximab treatment was reported in an 8-year-old child [41],
however, it was not clear whether it was caused by rituximab, as
ITP might be the first clinical manifestation before development of
common variable immunodeficiency. 1 patient developed head-
ache and MRI showing white matter changes [38], but without
detailed information as published only in abstract, it is not clear
whether the children developed progressive multifocal leukoen-
cephalopathy, although it is reported that there was a potential of
progressive multifocal leukoencephalopathy among rituximab-
treated patients [49]. No death was found in this review, but 9
cases of death (2.9%) were reported in studies on adults [9]. The
mortality reported in adults treated with rituximab might be
overestimated and these cases might be explained by long courses
of complex treatment regimens or the selection of patients with
advanced disease.
All the studies eligible for efficacy analysis in this review failed
to compare effect between rituximab with non-rituximab group.
The response rate obtained may be influenced by many potential
factors, such as treatments before and combined with rituximab,
cause and development of ITP. Studies on this topic with better
methodological design like randomized controlled studies are
urgently needed. Consecutive enrolling of patients can help to
reduce selection bias in prospective case series studies, unfortu-
nately, few studies provided information on that, and this needs
improvement in future studies.
Supporting Information
Table S1 Search strategy for PUBMED, EMBASE and
CENTRAL.
Figure 4. Begg funnel plot with pseudo 95% for studies reporting response. This plot is created by STATA 11.1. For each study, the
response rate is plotted against its standard error. The funnel plot suggests no significant asymmetry, indicating no evidence of substantial
publication bias.
doi:10.1371/journal.pone.0036698.g004
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